

ASX RELEASE

Apiam Animal Health Limited (ASX: AHX)

Apiam distribution partner Aurora Pharmaceutical receives regulatory approval to launch Xtend 21[®] Antimicrobial Surface Protectant in US

- **Apiam's distribution partner Aurora Pharmaceutical has received US EPA notification to market Xtend 21[®] Antimicrobial Surface Protectant**
- **Aurora Pharmaceutical is a rapidly growing veterinary pharmaceutical company, headquartered in the US with more than 10,000 veterinary customers**
- **US EPA notification follows extensive research and trial period by Apiam and Zoono Animal Health in various global markets to demonstrate efficacy**
- **Highly regarded industry trials at Iowa State University demonstrated 21 days surface protection after application**
- **Consistent with Apiam's long-term strategy to lead antimicrobial stewardship innovation within animal health segment**

Bendigo, November 15, 2021 – Apiam Animal Health Limited (**Apiam** or the **Company**) is pleased to announce that the US Environmental Protection Agency (US EPA) has notified Apiam's US distribution partner, Aurora Pharmaceutical, Inc. (Aurora Pharmaceutical) of label approval to market the Zoono Microbe Shield technology as **Xtend 21[®] Antimicrobial Surface Protectant** in the US market.

Apiam entered into an exclusive distribution agreement with Zoono Animal Health in March 2020 in respect of Zoono Group Limited's proprietary long-lasting surface protection technology system for use in agriculture, veterinary and animal health markets in the US.

Since being granted these distribution rights, Apiam and Zoono Animal Health have undertaken extensive third-party trials of the Zoono technology across various global markets, across animal premises including pig, poultry and veterinary facilities with highly successful results.

Apiam's Managing Director Dr Chris Richards said "We are very pleased that recent tests undertaken, particularly at the highly regarded Iowa State University, have demonstrated that this surface protectant continued to show enhanced surface protection 21 days after application. This is a first of its kind for the animal sector and we see this as very attractive for customers that face challenges with microbial surface contamination"

Innovation around antimicrobial technology is a key strategic focus for Apiam, as the livestock industry looks to reduce reliance on traditional antibiotic solutions.

About Aurora Pharmaceutical

Apiam has previously entered into an agreement with Aurora Pharmaceutical to distribute this innovative technology into key veterinary and animal health markets in the US and has been working with the company for some time to best position this product for commercialisation.

Aurora Pharmaceutical is a rapidly growing veterinary pharmaceutical product development and manufacturing business headquartered in Northfield, Minnesota, with over 10 years marketing veterinary pharmaceuticals.

The company currently supplies over 20 veterinary products into the North American veterinary industry predominantly to its customer base of over 10,000 veterinary clinics. A network of technical and sales representatives service the pig, poultry, cattle, equine and pet markets.

Aurora Pharmaceutical CEO and President, Dr Michael Strobel commented “We look forward to launching **Xtend 21**[®] Antimicrobial Surface Protectant into the US veterinary and livestock markets to enhance hygiene programs and provide long lasting antimicrobial surface protection.”

“We are also pleased to continue our working relationship with Apiam, who share our strategy of leading the way for evidence-based product innovation to optimise animal health outcomes. We see **Xtend 21**[®] as a valuable addition to our portfolio with significant market potential.”

Xtend 21[®] Label

The **Xtend 21**[®] product provides durable biostatic activity to the surface of a wide variety of substrates with reapplication recommended every 30 days. The label provides approval for use in veterinary practices, animal hospitals and surgeries, kennels, boarding facilities, and other animal care facilities.

Xtend 21[®] has the potential to be applied to air filters, cool cells, loadout chutes, cabins and on trailers of livestock vehicles, enhancing antimicrobial surface protection.

Recent tests undertaken at Iowa State University demonstrated that the product continued to show enhanced surface protection 21 days after application, even when that surface was washed with damp gauze at 7 and 14 days.

Xtend 21[®] is currently in the process of receiving final US state approvals and is expected to be launched in-market from January 2022.

Clinical Efficacy & Results Update

Over the last 20 months, Apiam and Zoono Animal Health have undertaken extensive third-party trials of the Zoono technology across various global markets. The product has shown outperformance of surface protectants with similar active ingredients. Strong duration of efficacy results has also been reported with repeated tests undertaken against common disinfectants showing highly improved outcomes.

University and industry veterinarians have successfully tested efficacy of the Zoono technology against several animal pathogens such as Porcine Reproduction and Respiratory Syndrome virus (PRRSv), Porcine Epidemic Diarrhea virus (PEDv) and African Swine Fever virus (ASFv).

--Ends--

For further information, please contact:

Dr Chris Richards
Managing Director
Apiam Animal Health Limited
chris@apiam.com.au

Catherine Ross
Investor Relations
catherine.ross@apiam.com.au
0421 997 481

Authorisation

This announcement was authorised by the Board of Directors of Apiam Animal Health Limited.

Investors are invited to keep up to date with Apiam news and industry research by subscribing at: <https://www.apiam.com.au/investor-subscribe>



27-33 Piper Lane East Bendigo 3550; PO Box 2388, Bendigo DC, Vic 3554

P: 03 5445 5999 E: enquiries@apiam.com.au W: apiam.com.au

ACN: 604 961 024

About Apiam Animal Health Limited

Apiam Animal Health is positioned in the Australian market as a vertically integrated animal health business providing a range of products and services to Production and Mixed animals. Apiam Animal Health's strategy is to service Production and Mixed animals throughout their lifecycle, including the provision of veterinary services, ancillary services, genetics, wholesale and retail of related products, together with technical services related to food-chain security.